The document's conclusion cannot be provided because the document is not available or cannot be read.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
50 citations
,
August 1985 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Spironolactone reduces the enzyme activity that converts testosterone to DHT, helping treat excessive hair growth in women.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
5 citations
,
February 2019 in “bioRxiv (Cold Spring Harbor Laboratory)” Rapamycin may help treat Leigh syndrome by targeting protein kinase C.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
March 2023 in “Reactions Weekly”
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
4 citations
,
March 2008 in “Journal of the American Academy of Dermatology” 294 citations
,
March 2016 in “European journal of cancer” Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.
May 2025 in “Reactions Weekly” March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
2 citations
,
March 2020 in “Cns & Neurological Disorders-drug Targets” Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.
January 2008 in “Projeto: revista mensal de arquitetura” Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
32 citations
,
August 1985 in “Clinical endocrinology” Spironolactone may help reduce hair growth and testosterone levels in some women with hirsutism.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
18 citations
,
May 2020 in “Biomolecules” Spironolactone, a heart and liver drug, has new uses including cancer treatment, viral infection prevention, and skin condition improvement.
September 2024 in “Journal of the American Academy of Dermatology” The new hair treatment significantly reduces hair shedding safely.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
January 2023 in “Rasayan journal of chemistry/Rasayan journal of Chemistry” Methyl pyropheophorbide A from Sansevieria trifasciata leaves may help treat hair loss.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
November 2007 in “Hospital pharmacy” The conclusion is that healthcare professionals should report adverse drug reactions to improve medication safety and patient care.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
September 2023 in “Journal of the American Academy of Dermatology”
December 2025 in “Clinical & Experimental Dermatology and Therapies” Cosmerna ARI effectively reduces hair loss and increases hair density in Europeans with androgenetic alopecia.
February 2012 in “Reactions Weekly” A woman got male pattern baldness from touching her husband's testosterone gel.
12 citations
,
April 1987 in “PubMed” Low-dose spironolactone is safe and effective for treating hirsutism.